We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immunohistochemical Stain Facilitates cHL Diagnosis

By LabMedica International staff writers
Posted on 11 Mar 2019
Remarkable efforts are underway to exploit classic Hodgkin lymphoma's (cHL) complex interplay of molecular alterations, loss of B-cell programming, and dependency of tumor microenvironment.

Tumor necrosis factor receptor superfamily member 9 or CD137 has been shown to induce proliferation and enhance the survival and function of T cells, natural killer cells, and dendritic cells. More...
Conceptually, agonistic anti-CD137 is categorized as a co-stimulatory immunotherapy with the potential to manipulate the tumor microenvironment and accentuate antitumor response.

Pathologists at the Naval Medical Center Portsmouth (Portsmouth, VA, USA) and The University of New Mexico School of Medicine (Albuquerque, NM, USA) constructed tissue microarrays from formalin-fixed, paraffin-embedded tissue including 42 cases of cHL, 33 cases of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), 16 cases of anaplastic large cell lymphoma, and seven cases of T-cell/histiocyte–rich large B-cell lymphoma. They validated anti-CD137 monoclonal BBK-2 clone, using protease retrieval and a dilution of 1:100.Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30 and reviewed by two pathologists.

The scientists assigned positive staining if 20% or more of the malignant cells were positive regardless of strength of staining. Of the cHL cases, 76% were positive for CD137, 85% were positive for CD15, 100% were positive for CD30, and 13% were positive for CD20. Interestingly, CD137 was positive in all cHL cases where CD15 was negative. Conversely, CD15 was positive in 88% of cHL cases that were negative for CD137. Furthermore, CD137 was positive in 6% of NLPHL cases, 38% of anaplastic large cell lymphoma cases, and in none of the T-cell/histiocyte–rich large B-cell lymphoma cases.

The authors concluded that, although CD137 is not specific for cHL, it has utility in the immunohistochemistry (IHC) evaluation for cHL, in particular when the morphologic distinction with NLPHL is challenging. Additionally, it is easy to interpret, with minimal nonspecific background staining. Lastly, CD137 expression has been identified in several solid and hematopoietic neoplasms, and determination of this expression via IHC may prove to be a valuable biomarker of response to CD137 immunotherapy. The study was published in the March 2019 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Naval Medical Center Portsmouth
University of New Mexico School of Medicine


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.